Last reviewed · How we verify
NCT05162456: DANTE-SIRIO 8
Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation
trial testing assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule in SARS-CoV2 Infection in 250 participants. Status unknown.
28 February 2023
Quick facts
| Lead sponsor | Collegium Medicum w Bydgoszczy |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 1 July 2021 |
| Primary completion | 28 February 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
Conditions studied
- SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →
- SARS-CoV2 Antibodies — all drugs for SARS-CoV2 Antibodies →
Sponsor
Collegium Medicum w Bydgoszczy — full company profile →
Who can join
18 and older, any sex, with SARS-CoV2 Infection or SARS-CoV2 Antibodies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Great expectations to control the pandemic are placed in vaccines against COVID-19. Currently, the four COVID-19 vaccines approved in the European Union. The investigators designed a study assessing the anti-SARS-CoV-2 IgG antibody titer after vaccination cycle with the BNT162b2 vaccine in several time points relating these results to the COVID-19 history and severity of symptoms during the disease and after the first and second vaccine dose.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05162456
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
Trials testing the same drug.
- NCT05109585 — Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study · unknown
Other recruiting trials for SARS-CoV2 Infection
Currently open trials in the same condition.
- NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
- NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting
Other Collegium Medicum w Bydgoszczy trials
Trials by the same sponsor.
- NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
- NCT07231939 — Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI · recruiting
- NCT05905965 — Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment · Phase 3 · recruiting
- NCT05779059 — Prasugrel Or Ticagrelor De-escalation in NSTE-ACS · Phase 3 · unknown
- NCT04718025 — Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndro · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05162456 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Collegium Medicum w Bydgoszczy
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162456.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing